Bausch Health Companies Azioni (NYSE: BHC)

Ultime notizie per Bausch Health Companies (NYSE:BHC) Azioni

Bausch Health Companies

Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Bausch Health Cos

Bausch Health Companies Inc. Common Stock

Bausch Health Companies Inc

BillionHappiness

BENCHMARK HLDGS PLC by Benchmark Hldgs PLC

Benchmark Holdings PLC

Gap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) shares soared by 14.02% on Friday during pre-market hours, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, following the release of its third-quarter earnings report after Thursday&#8217;s market close. The retailer exceeded Wall Street expectations, leading to a positive revision in its annual sales outlook.
The <a href="https://www.benzinga.com/news/earnings/24/11/42125007/gap-stock-soars-on-better-than-expected-q3-results-raised-fy-guidance-details">company reported earning</a>s of 72 cents per share, surpassing the analyst consensus of 57 cents. Revenue for the quarter reached $3.82 billion, slightly above the anticipated $3.81 billion and marking an increase from last year&#8217;s $3.76 billion for the same period.
See Also: <a href="https://www.benzinga.com/24/11/42053687/peter-schiff-pokes-fun-at-microstrategys-bitcoin-buying-spree-michael-saylor-is-gonna-need-a-bigger-plan?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Peter Schiff Pokes Fun Of MicroStrategy&#8217;s Bitcoin Purchase: &#8216;Michael Saylor Is Gonna Need A Bigger Plan&#8217;</a>
Net sales rose by 2% compared to the previous year, with comparable sales increasing by 1%. The operating margin improved to 9.3%, up 270 basis points from the prior year.
Looking ahead, Gap has adjusted its full-year projections, now expecting net sales to rise between 1.5% and 2%. The company also anticipates a&nbsp;gross margin growth of 220&nbsp;basis points and an operating income margin in the mid-to-high 60% range. This optimistic outlook has contributed to the stock&#8217;s recent rally.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42102769/floki-beats-dogecoin-shiba-inu-with-double-digit-gains-after-coinbase-listing-announcement?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Floki Beats Dogecoin, Shiba Inu With Double-Digit Gains After Coinbase Listing Announcement</a></li>
</ul>
Image by Raysonho via Wikimedia Commons

Equities

News

Pre-Market Outlook

Markets

General

GAP Stock Surges 14% In Friday Pre-Market After Boosting Sales Forecast

Needham analyst Matt Dezort reiterates Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Hold.

Reiteration

Analyst Ratings

FTNT

Needham Reiterates Hold on Fortinet

As the U.S. dollar scaled a fresh 52-week high on Friday morning at 108.071 level, former Goldman Sachs FX strategist and senior fellow at Brookings Institution, Robin Brooks said in an X (formerly Twitter) post that, &#8220;Markets initially got this wrong, driving stocks up sharply right after Nov. 5.&#8221;
He added that &#8220;the prospect of tariffs isn&#8217;t obviously good for equities, while it&#8217;s clearly good for the Dollar. More Dollar strength is coming.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The Dollar (lhs) is now clearly outperforming S&amp;P 500 (rhs). Markets initially got this wrong, driving stocks up sharply right after Nov. 5. But the prospect of tariffs isn&#39;t obviously good for equities, while it&#39;s clearly good for the Dollar. More Dollar strength is coming&#8230; <a href="https://t.co/GEZr0IaDh8">pic.twitter.com/GEZr0IaDh8</a>
&mdash; Robin Brooks (@robin_j_brooks) <a href="https://twitter.com/robin_j_brooks/status/1859894280149717359?ref_src=twsrc%5Etfw">November 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Also read: <a href="https://www.benzinga.com/24/11/42088394/economist-gordon-johnson-slams-federal-reserve-for-asset-owner-centric-policies-says-fed-needs-to-focus-on-the-real-economy-over-stock-markets" target="_blank" rel="noreferrer noopener">Gordon Johnson Slams Federal Reserve For Asset-Owner Centric Policies, Says Jerome Powell Needs To Focus On ‘Real Economy': ‘…The Stock Market Will Be Fine'</a>
What Happened: A chart shared by Brooks compared the S&amp;P 500 Index and the Dollar Index during President-elect Donald Trump&#8217;s victory in 2016 and 2024. Measuring the performance of both indices from the day of the election on Nov. 5, the Dollar Index has risen by approximately 3.5%, outperforming the S&amp;P 500 Index, which advanced 2.9%.
Why It Matters: An <a href="https://www.benzinga.com/24/11/41939162/us-treasuries-edge-up-as-trumps-proposed-policies-possible-rate-cut-may-rekindle-inflation-fears-all-eyes-on-federal-reserves-next-steps">increase in tariffs</a> reduces the demand for imported goods and lifts domestic prices above the free trade price, gradually stoking inflation. This results in monetary tightening affecting the equities in the long run.
However, higher tariffs are positive for the domestic currency as its supply decreases and more money flows into the economy.
What Are Other Analysts Saying: Now that the Dollar Index has surpassed its previous 52-week high of 107.07, &#8220;a break of it may let <a href="https://www.benzinga.com/24/11/42103600/us-dollar-may-test-10860-level-as-geopolitical-tensions-cautious-fed-rhetoric-and-solid-us-economic-data-may-push-the-greenback-higher-says-expert">it test 108.60 </a>while 105.10 acting as a support,&#8221; said Kunal Sodhani, vice president of the global trading center at Shinhan Bank.
According to him, &#8220;the ongoing geopolitical tensions in the Middle East combined with the strong U.S. economic data and the Federal Reserve's cautious rhetoric on interest rate cuts, may push the U.S. Dollar to new highs&#8221;
As of Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) had gained 25.60% year-to-date, while the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) saw a 25.43% increase, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. Despite these strong returns, both ETFs were slightly down in pre-market trading on Friday.
Meanwhile, the <a href="https://www.benzinga.com/24/11/42133364/us-stocks-on-edge-but-likely-to-end-the-week-in-the-green-trumps-treasury-pick-in-focus-expert-says-case-for-fed-pause-in-december-getting-stronger">futures show a decline across major indices</a>: Nasdaq 100 down 0.51%, S&amp;P 500 down 0.40%, Dow Jones down 0.29%, and R2K down 0.08%.
Read next: <a href="https://www.benzinga.com/24/11/42103600/us-dollar-may-test-10860-level-as-geopolitical-tensions-cautious-fed-rhetoric-and-solid-us-economic-data-may-push-the-greenback-higher-says-expert">Dollar Upside On The Cards Amid Geopolitical Tensions, Cautious Fed And Solid US Economic Data, Says Expert</a>
Image via Wikimedia Commons

Macro Economic Events

Forex

Economics

Markets Misread Trump Win, Says Ex-Goldman Sachs Analyst: 'Prospects Of Tariffs Not Good For Equities'

Needham analyst Laura Martin downgrades Innovid (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTV#NYSE">CTV</a>) from Buy to Hold and maintains the price target from $3 to $3.

Downgrades

Price Target

Needham Downgrades Innovid to Hold, Maintains Price Target to $3

Financial guidance and long-term targets The macro and microeconomic environment in which Global Blue operates remains highly favorable. The travel industry is experiencing positive trends, particularly in the high-end segment, and Global Blue has made significant progress in implementing strategic initiatives to further penetrate the market. In parallel, Global Blue has continued to outperform in the luxury market, driven by its unique exposure to affluent and high-net-worth international shoppers. That said, considering the recent luxury market slowdown and taking into account the Group's decision to accelerate €5 million of investments (fixed costs) in future growth initiatives (expansion into new countries, adaptation of Japan's business model and Hospitality Gateway), we have adapted our FY24/25 Adjusted EBITDA guidance to €185 million - $205 million.
Long-term targets include 8-12% revenue growth, &gt;50% drop-through, and a net leverage ratio of &lt;2.5x.

Guidance

Global Blue Expects FY24/25 Adj EBITDA Of €185M-€205M (Prior More Than €200M)

Needham analyst Mike Cikos reiterates N-able (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NABL#NYSE">NABL</a>) with a Buy and maintains $16.5 price target.

NABL

Needham Reiterates Buy on N-able, Maintains $16.5 Price Target

Earnings

Earnings Beats

Global Blue Gr Holding Q2 Sales €132.000M Beat €131.250M Estimate

Ahead of the potential market correction,&nbsp;Brian Arcese&nbsp;from&nbsp;Foord Asset Management&nbsp;has highlighted concerns over the U.S. economic growth and corporate earnings. These factors could trigger a correction if they continue to slow down.
What Happened: Arcese warned that a market correction could occur if U.S. GDP or earnings growth slows. Arcese noted that the S&amp;P 500 has&nbsp;been &#8220;expensive for quite a&nbsp;while,&#8221; with a price-to-earnings ratio exceeding 27, CNBC <a href="https://www.cnbc.com/2024/11/22/sp-correction-could-happen-if-gdp-or-earnings-growth-slows-says-asset-manager.html">reported</a>&nbsp;on Friday.
"We do think that a correction would be healthy, but you will need some type of catalyst for that correction to take place,&#8221; he said, highlighting two potential catalysts for a correction: slowing economic growth and inflation increases. 
U.S. GDP growth was less than anticipated in the third quarter, and&nbsp;inflation rose to 2.6% in&nbsp;October, as per recent data. He emphasized that high corporate earnings expectations, particularly outside IT and communication services, could also trigger a correction if growth slows.
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42079585/meta-google-and-microsoft-bet-big-on-ai-with-skyrocketing-capex-budgets-but-jensen-huangs-nvidia-poised-to-be-the-biggest-winner-says-analyst-only-game-in-town-with-1-trillion-of-ai-capex?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dan Ives Expects &#8216;Drop The Mic Performance&#8217; Tomorrow From Nvidia: Here&#8217;s Why</a>
Arcese remarked on the unusual combination of factors like GDP growth, earnings growth, and&nbsp;falling inflation and interest rates, which he described as rare. He noted that while utilities are more expensive than before, they remain less costly than the broader market, with growth driven by increased electricity demand from data centers and AI advancements.
Why It Matters: The concerns raised by Arcese align with recent warnings from other financial experts.&nbsp;David Einhorn, founder of Greenlight Capital<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42087680/billionaire-investor-david-einhorn-calls-it-most-expensive-market-of-all-time-as-sp-500-gains-4-since-trumps-win-really-really-pricey">, recently labeled the current market</a> as &#8220;the most expensive of all time,&#8221; citing the high Shiller cyclically adjusted price-to-earnings ratio.
Similarly,&nbsp;Stifel&#8217;s&nbsp;Barry Bannister predicted a <a href="https://www.benzinga.com/markets/equities/24/09/40974512/stifel-warns-of-12-market-drop-by-end-of-2024-as-s-p-500-faces-high-valuations-and-speculative-r">12% market drop</a> by the end of 2024, driven by high valuations and speculative risks. The S&amp;P 500&#8217;s price-to-earnings multiple is nearing historic highs, reminiscent of previous market peaks.
Despite these concerns,&nbsp;<a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42024472/goldman-sachs-us-to-dominate-2025-growth-with-2-5-gdp-boost-euro-area-will-struggle">Goldman Sachs&nbsp;forecasts </a>strong U.S. economic growth in 2025, with a 2.5% GDP boost, suggesting potential resilience in the face of current market challenges.
Price Action: As of Friday, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) that tracks the S&amp;P 500 closely witnessed a 25.60% increase in its year-to-date (YTD) returns while Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) saw a hike of 25.43%. However, during pre-market hours on Friday, both the ETFs were trading slightly lower.
On Friday, <a href="https://www.benzinga.com/24/11/42133364/us-stocks-on-edge-but-likely-to-end-the-week-in-the-green-trumps-treasury-pick-in-focus-expert-says-case-for-fed-pause-in-december-getting-stronger">futures show a decline across major indices</a>: Nasdaq 100 down 0.51%, S&amp;P 500 down 0.40%, Dow Jones down 0.29%, and R2K down 0.08%.
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42082077/if-you-bought-bitcoin-at-387-a-decade-ago-you-would-now-have-more-than-2x-the-average-us-retirement-savings?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">If You Bought Bitcoin At $387 A Decade Ago, You Would Now Have More Than 2X The Average US Retirement Savings</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Analyst Color

Potential 'Healthy Correction' For An 'Expensive' Market Looms As US Economic Growth And Earnings Slow, Says Asset Manager: S&P 500, Nasdaq Futures Trade Lower In Premarket

KBR Inks Pact With AMUFERT For The Development Of A New Ammonia Plant In Soyo, Angola

The company said its subsidiary Beneficient Company Holdings, L.P. consummated a previously announced transaction pursuant to which approximately $35 million of its preferred equity was redesignated as non-redeemable, resulting in the addition of approximately $35 million of permanent equity on its balance sheet.&nbsp;

BENF

Beneficient Says It Believes It Now Has Stockholders' Equity Of At Least $2.5M, The Amount Required To Regain Compliance With Nasdaq's Minimum Stockholders' Equity Requirement

SCLX

Scilex Holding Company Announces Receipt Of Notice From Nasdaq For Its Failure To File Its Quarterly Report On Form 10-Q For The Quarter Ended September 30

Needham analyst Tom Nikic initiates coverage on Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) with a Hold rating.

Initiation

Needham Initiates Coverage On Skechers USA with Hold Rating

This milestone follows Tri Pointe Homes' entry into the greater Orlando market, a strategic expansion driven by the area's robust growth and demand for high-quality housing options.

Tri Pointe Homes Says It Closed On First Land Acquisition In The Greater Orlando Market, Marking The Homebuilder's Debut In Minneola's Sugarloaf Mountain Community

Needham analyst Tom Nikic initiates coverage on Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Hold rating.

LULU

Needham Initiates Coverage On Lululemon Athletica with Hold Rating

Needham analyst Tom Nikic initiates coverage on Crocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) with a Buy rating and announces Price Target of $116.

CROX

Needham Initiates Coverage On Crocs with Buy Rating, Announces Price Target of $116

Needham analyst Tom Nikic initiates coverage on Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Hold rating.

SHOO

Needham Initiates Coverage On Steven Madden with Hold Rating

U.S. stocks could open on a negative note on Friday after futures showed tentativeness on Friday. Investors turned their focus to cyclical stocks and themes, moving on from their <a href="https://www.benzinga.com/24/11/42058223/us-stocks-likely-to-open-in-red-as-geopolitical-tension-weigh-on-investor-sentiment-wharton-economist-says-market-trajectory-will-heavily-depend-on-trumps-tariff-plans">focus on the Trump trade</a> after the election results.
Futures of the three major indices were mixed, with the Nasdaq heading lower after AI giant Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) posted its highly-anticipated third-quarter results.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.51%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.40%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.29%</td>
</tr>
<tr>
<td>R2K</td>
<td>-0.08%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) edged lower by 0.34% to $591.68 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) declined 0.39% to $503.03, according to <a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
U.S. stocks ended Thursday in the green, with the Dow Jones surging by over 450 points, while the tech-heavy Nasdaq registered marginal gains.
Crude oil futures continued on their upward trajectory amid rising tensions between Russia and Ukraine.
Treasury yields eased marginally on mixed data and the declining probability of the Federal Open Market Committee (FOMC) cutting interest rates in December.
On the economic data front, U.S. existing home sales gained 3.5% from the previous month to an annualized rate of 3.96 million in October. The Philadelphia Fed Manufacturing Index fell to -5.5 in November from 10.3 in the previous month, and compared to market estimates of 8.
Initial jobless claims declined by 6,000 from the previous week to 213,000 in the week ending Nov. 16.
Most sectors on the S&amp;P 500 closed on a positive note, with utilities, financials, and consumer staples stocks recording the biggest gains on Thursday.
However, consumer discretionary and communication services stocks bucked the overall market trend, closing the session lower.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.03%</td>
<td>18,972.42</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.53%</td>
<td>5,948.71</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>1.06%</td>
<td>43,870.35</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.65%</td>
<td>2,364.02</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Powell's relatively hawkish tone has investors cautious in the markets. With the Trump trade losing steam, the focus is now on the President-elect's Treasury pick.
"In focus currently is President-elect Trump's pick for the influential post of US Treasury Secretary. Given the large US budget deficit, investors will probably want to see a safe pair of hands being chosen," ING analysts said in a note.
With the next rate cut now a coin toss, the U.S. dollar could see a correction. According to ING analyst Francesco Pesole, the dollar is "testing the limit" of its longs and traders should exercise caution for the time being.
"Powell seemed to put greater emphasis on the strength of the economy&nbsp;and how that allows the central bank to approach the upcoming policy decisions ‘carefully'."
CME Group's FedWatch tool <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">reflected</a> the fall in sentiment for another rate cut next month, with its probability declining to 59.6% from 72.2%.
&#8220;The case for a Fed pause in December is getting stronger and Fed officials are communicating that they are open to it going into the next meeting,&#8221; Kathy Jones, chief fixed income strategist at Schwab, said in a recent note.
&#8220;It will come down to employment and inflation data.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
Friday's major economic updates include:
<ul>
<li>S&amp;P U.S. Services and Manufacturing Purchasing Manager's Index will be released at 9:45 a.m. ET.</li>
<li>Consumer sentiment data will be released at 10 a.m. ET.</li>
<li>Fed Gov. Michelle Bowman will speak at 6:15 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>The Gap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) stock surged 15% in premarket trading after the <a href="https://www.benzinga.com/news/earnings/24/11/42125007/gap-stock-soars-on-better-than-expected-q3-results-raised-fy-guidance-details">retailer raised its annual target</a> with a "strong" outlook for the holiday season.</li>
<li>MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) stock surged over 2% in premarket trading on Friday as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">inched closer to the $100,000 mark</a>. Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) stock was also up over 0.5%.</li>
<li>Reddit Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) stock <a href="https://www.benzinga.com/24/11/42132644/reddit-falls-7-in-afterhours-as-advance-plans-stake-sale-technicals-show-strong-support-but-selling-pressure-persists-at-overbought-levels">fell over 7% in premarket trading</a> after the social media company amid Advance's stake sale announcement.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) stock fell over 4.7% on Thursday after the U.S. Department of Justice (DOJ) pushed forward with its demands for <a href="https://www.benzinga.com/24/11/42131274/why-googles-chrome-battle-isnt-just-about-search-gene-munster-calls-it-a-tough-day-for-big-tech-on-the-regulatory-front">Google to divest</a> the Chrome web browser.</li>
<li>Investors are awaiting earnings results from Destination XL Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) and Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures rose in the early New York session, surging by 0.61% to hover around $70.54 per barrel.
The 10-year Treasury note yield eased to 4.396%.
Most of the major Asian markets ended in the green on Friday, but European markets were mixed in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">Bitcoin&#8217;s Path To $100K &#8216;Inevitable&#8217; But Crypto Community Is &#8216;Leveraged To The Gills,&#8217; Warns Galaxy&#8217;s Mike Novogratz, Predicts Correction To $80K Ahead</a></li>
</ul>
Photo courtesy: Wikimedia

Futures

Federal Reserve

Movers

Trading Ideas

$BTC

DXLG

GOOG

GOOGL

HOOD

MSTR

NVDA

RDDT

US Stocks Set To Open Lower On Friday As Investors Eye Cyclical Stocks: Trump's Treasury Pick In Focus, Expert Says Case For Fed Pause In December 'Getting Stronger'

Needham analyst Tom Nikic initiates coverage on Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Buy rating and announces Price Target of $218.

DECK

Needham Initiates Coverage On Deckers Outdoor with Buy Rating, Announces Price Target of $218

Shares of Elastic N.V (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and issued FY25 guidance <a href="https://www.benzinga.com/quote/ESTC/news">above estimates</a>.
Elastic reported quarterly earnings of 59 cents per share which beat the analyst consensus estimate of 38 cents per share. The company reported quarterly sales of $365.361 million which beat the analyst consensus estimate of $355.900 million.
Elastic shares jumped 29.1% to $121.46 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) gained 67.1% to $0.9855 in pre-market trading after the company announced an agreement with the US HHS department for an extension towards its cooperative research and development.</li>
<li>Wellchange Holdings Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) rose 50.4% to $1.88 in pre-market trading after dipping 62% on Thursday.</li>
<li>Beneficient  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) gained 30.7% to $1.15 in pre-market trading after gaining around 7% on Thursday.</li>
<li>SKK Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKK#NASDAQ">SKK</a>) gained 25.4% to $1.38 in pre-market trading after declining around 75% on Wednesday.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) gained 19.4% to $12.98 in pre-market trading.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) gained 14.9% to $25.33 in pre-market trading after reporting better-than-expected third-quarter results.</li>
<li>Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) gained 10.4% to $6.90 in pre-market trading.</li>
<li>Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>) climbed 8.7% to $1.63 in pre-market trading.</li>
<li>Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) gained 7% to $153.01 in pre-market trading after the company reported better-than-expected third-quarter EPS results..</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Knightscope, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) shares tumbled 41.8% to $10.64 in pre-market trading after the company announced the pricing of $12.1 million public offering.</li>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) fell 33.3% to $9.01 in pre-market trading.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) shares fell 27.2% to $0.1430 in pre-market trading after the company announced its board approved a 1-for-35 reverse stock split.</li>
<li>Procaps Group S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) declined 18.7% to $0.90 in pre-market trading as the company said it faced Nasdaq delisting threat due to Form 20-F filing delay.</li>
<li>Carter Bankshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARE#NASDAQ">CARE</a>) shares fell 10.6% to $16.86 in pre-market trading.</li>
<li>Real Messenger Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMSG#NASDAQ">RMSG</a>) dipped 16.2% to $3.51 in pre-market trading after jumping over 10% on Thursday.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) fell 13.9% to $0.21 in pre-market trading after dipping more than 10% on Thursday.</li>
<li>Envoy Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares dipped 12.7% to $1.92 in pre-market trading.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) fell 7.3% to $146.50 in pre-market trading. Reddit's shareholder, Advance Magazine Publishers Inc. plans to sell as much as $1.2 billion of the company's stake, reported Bloomberg on Friday morning. The company is said to be offering 7.8 million shares in between the range of $145.38-$148.54 each.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) fell 5.7% to $639.95 in today's pre-market trading. Intuit reported upbeat results for its first-quarter results, but issued weak forecast for the current quarter.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42131399/dow-surges-over-450-points-investor-sentiment-improves-fear-greed-index-moves-to-greed-zone">Dow Surges Over 450 Points As Nvidia Climbs Post-Earnings, Google, Amazon Slip: Fear Index Shifts To &#8216;Greed&#8217; Zone</a></li>
</ul>

AMIX

APTO

CARE

CETX

Envoy Medical, Inc. - Class A Common Stock

COCH

ESTC

INTU

KAPA

KSCP

PROC

RMSG

ROST

VRPX

XCUR

Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket

Needham analyst Tom Nikic initiates coverage on Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) with a Buy rating and announces Price Target of $27.

Needham Initiates Coverage On Foot Locker with Buy Rating, Announces Price Target of $27

Bausch Health Companies (TSE:BHC) has released an update. Bausch Health Companies reported a strong third quarter of 2024, achieving a 12% increase...

Bausch Health Reports Strong Growth in Q3 2024

Bausch Health Companies GAAP EPS of -$0.23 misses by $0.37, revenue of $2.51B beats by $90M

Bausch Health raises 2024 revenue guidance

Bausch Health Companies Inc. 2024 Q3 - Results - Earnings Call Presentation

Bausch Health Companies ( ($BHC) ) has realeased its Q3 earnings. Here is a breakdown of the information Bausch Health Companies presented to its i...

Bausch Health Reports Growth Amid Improved Financials

Truist Financial analyst Les Sulewski maintained a Hold rating on Bausch Health Companies (BHC – Research Report) today and set a price target of $...

Truist Financial Keeps Their Hold Rating on Bausch Health Companies (BHC)

Steve Scala, an analyst from TD Cowen, maintained the Hold rating on Bausch Health Companies (BHC – Research Report). The associated price target i...

Bausch Health Companies: Hold Rating Amid Mixed Financial Performance and Strategic Uncertainty

Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly exploring a potential sale in ...

Bausch + Lomb (BLCO) Posts Impressive Revenue and Explores Potential Sale

Bausch Health (BHC) Companiesannounced the first look at its late-stage RED-C clinical trial program which will be presented at the American Associ...

Bausch Health, Salix to present RED-C Phase 3 study design

Bausch Health (BHC) announced that CABTREO gel 1.2% w/w, 0.15% w/w and 3.1% w/w, a new triple-combination topical prescription treatment for acne v...

Bausch Health announces CABTREO receives positive reimbursement recommendations

BLCO

Management

Press Releases

Bausch Health Welcomes Two New Members to the Executive Leadership Team

Bausch Health Responds to Market Rumors

Bausch Health Announces Second Quarter 2024 Results

Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older

Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises

Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

Events

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

Bausch Health Announces Third Quarter 2024 Results

Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis

PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS

Comments

Bausch Health Companies

Notizie

Ultime notizie per Bausch Health Companies (NYSE:BHC) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO